ONCOBAX®-AK, a game-changer Live Biotherapeutic Product for anticancer immunotherapy
Time: 5:30 pm
day: Day One – Track B – 3
- The composition of the gut microbiota influences the effectiveness of anticancer immunotherapy
- EverImmune has developed Oncobax®-AK, a breakthrough microbiome technology as oral adjuvant for anticancer immunotherapy in
- NSCLC and RCC patients treated with ICIs, that will enter into clinics 2nd quarter 2022.
- EverImmune has developed companion diagnosis tools to identify patients amenable to Oncobax®-AK